Polpharma Biologics Announces U.S. Availability of Tyruko®, the First FDA-Approved Natalizumab Biosimilar
Ajinomoto Co. and Forge Biologics Develop Culture Media Supplements to Improve Gene Therapy Productivity
Genezen Partners with Humane Genomics for cGMP Manufacturing of Novel Pediatric Cancer Therapy HGI627
Polpharma Biologics Announces U.S. Availability of Tyruko®, the First FDA-Approved Natalizumab Biosimilar
Ajinomoto Co. and Forge Biologics Develop Culture Media Supplements to Improve Gene Therapy Productivity
Genezen Partners with Humane Genomics for cGMP Manufacturing of Novel Pediatric Cancer Therapy HGI627